A groundbreaking international consensus effort has, for the first time, established detailed expert guidance on how to safely deliver CPX-351, a liposomal formulation of cytarabine and daunorubicin, to patients with therapy-related acute myeloid leukaemia (t-AML) and acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC) outside the traditional hospital ward. The study, published in Annals of Hematology, used a modified Delphi methodology, a structured technique for achieving group agreement among experts, to build a practical roadmap for outpatient administration of this intensive chemotherapy regimen. As health systems worldwide grapple with capacity pressures, aging populations, and rising demand for oncology services, the findings arrive at a pivotal moment, offering clinicians a validated framework for shifting carefully selected patients away from inpatient care without compromising safety or treatment quality.
CPX-351 is not an ordinary chemotherapy combination. It encapsulates cytarabine and daunorubicin within liposomes at a fixed five-to-one molar ratio, allowing the two agents to be delivered together and to persist in the bloodstream for longer than conventional formulations. This pharmacokinetic profile improves drug uptake by leukaemic blasts and has demonstrated clinical benefit for patients whose disease arises from prior therapy or carries myelodysplasia-related genetic changes, groups that historically fared poorly with standard induction regimens. Because the drug can be administered in both inpatient and outpatient settings, clinicians have increasingly explored ambulatory delivery as a way to spare hospital beds, reduce exposure to nosocomial infections, and preserve patients’ autonomy during a demanding course of intensive treatment.
To formalize this practice, a steering group of nine haematologists with hands-on experience in outpatient CPX-351 treatment was assembled from institutions across Europe and Australia. The group drafted a series of consensus statements organized into six key domains covering patient selection, definitions of treatment settings, the anticipated benefits of outpatient care, patient and caregiver requirements, healthcare system prerequisites, and practical measures for optimizing delivery. Their statements were then subjected to validation by a much wider panel: an online survey of 200 haematologists drawn from Australia, France, Germany, Italy, the United Kingdom, and Spain, all of whom had experience with intensive chemotherapy and outpatient care for AML. Agreement was measured on a four-point Likert scale, with consensus defined as at least seventy-five percent agreement for each statement.
The results were strikingly decisive. Forty-two of the forty-three statements, ninety-eight percent of the total, achieved consensus, and thirty-one of them reached agreement levels of ninety percent or higher. Such near-unanimity among two hundred specialists spanning six countries and diverse healthcare systems is uncommon in Delphi studies and signals that the clinical community has converged on a coherent view of how outpatient CPX-351 delivery should be approached. High alignment emerged particularly around the identification of suitable patients and the definition of what constitutes an appropriate outpatient treatment setting, the foundational questions that determine whether a given individual can safely receive intensive liposomal chemotherapy without overnight admission to a hematology ward.
When it came to the benefits of outpatient treatment, the panel expressed its strongest agreement on potential advantages for hospital resourcing, an issue of acute relevance as many hematology units face chronic bed shortages. Respondents also strongly endorsed improvements in patients’ physical and psychological status and in quality of life, reflecting a broader movement in oncology toward care models that respect patients’ daily lives. For older or comorbid patients with t-AML or AML-MRC, who may already be coping with the consequences of prior malignancy treatment, the ability to undergo induction chemotherapy while sleeping in their own beds, staying connected to family, and avoiding the disorientation of prolonged hospitalization carries real therapeutic and emotional weight.
The consensus did not shy away from the prerequisites that make such a model viable. The survey highlighted significant agreement on key patient and caregiver requirements, including cognitive and physical abilities sufficient to recognize and report emerging problems, reliable communication channels with the treating team, and reasonable access to the hospital or an affiliated emergency facility. These criteria acknowledge the central paradox of ambulatory intensive chemotherapy: the treatment is administered outside the ward, but the risk of febrile neutropenia, bleeding, and other complications remains, so patients must be selected, educated, and supported with the same rigor applied to any inpatient induction regimen.
Healthcare system requirements formed another domain of strong agreement. Respondents emphasized the need for explicit hospital protocols, adequate available resources, and robust systems for managing complications when they arise. In practice, this means that outpatient CPX-351 programs cannot simply be layered onto existing services without investment. They demand dedicated staff training, clearly defined escalation pathways, rapid-access clinics or equivalent mechanisms for same-day assessment, and coordination across the multidisciplinary team, including haematologists, nurses, pharmacists, and emergency physicians who may encounter these patients between scheduled visits. The consensus framework effectively functions as a checklist for institutions considering launching such a service.
Beyond eligibility and infrastructure, the panel endorsed a set of practical measures to optimize day-to-day delivery. These included the use of patient assessment tools to standardize selection and monitoring, structured collection of patient feedback, ongoing staff education, deliberate coordination among multidisciplinary team members, and the systematic sharing of best practices across centers. Although the authors acknowledge that challenges may differ across countries and healthcare settings, with reimbursement structures, geographic distances, and staffing models varying widely, the consensus provides clear, transferable guidance on safe and effective outpatient administration. For centers with less experience in ambulatory delivery of CPX-351, the document offers a ready-made starting point grounded in the collective judgment of the international hematology community.
The significance of this work extends beyond a single drug. Intensive chemotherapy for acute myeloid leukaemia has traditionally been synonymous with weeks of hospitalization, a model that burdens patients, families, and health systems alike. As liposomal and targeted therapies broaden the options for older and frailer patients, and as ambulatory care models prove their worth in other malignancies, structured consensus documents like this one will play an increasingly important role in translating clinical trial evidence into safe everyday practice. The near-total agreement achieved here suggests that outpatient CPX-351 treatment for t-AML and AML-MRC is no longer an experimental convenience but an emerging standard of care, provided that centers adhere to the patient-selection criteria, monitoring requirements, and multidisciplinary safeguards that the international panel has now so clearly defined.
Subject of Research: Outpatient delivery of CPX-351 liposomal cytarabine-daunorubicin for therapy-related acute myeloid leukaemia and AML with myelodysplasia-related changes
Article Title: Optimising CPX-351 (liposomal cytarabine-daunorubicin) treatment for t-AML/AML-MRC patients in the outpatient setting: a modified Delphi consensus
Article References: Mehta, P., MartĂnez-Roca, A., Cahalin, P., McNamara, C., Salamero, O., Martelli, M. P., Franke, G.-N., Capelli, D., de AndrĂ©s-Nogales, F., Francia, R., Lassman, E., & Conn, J. (2026). Optimising CPX-351 (liposomal cytarabine-daunorubicin) treatment for t-AML/AML-MRC patients in the outpatient setting: a modified Delphi consensus. Annals of Hematology. https://doi.org/10.1007/s00277-026-07220-9
Image Credits: AI Generated
DOI: 10.1007/s00277-026-07220-9
Keywords: CPX-351, acute myeloid leukaemia, t-AML, AML-MRC, liposomal cytarabine-daunorubicin, outpatient care, Delphi consensus, haematology, chemotherapy, ambulatory care, patient selection, quality of life
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 12, 2026). Experts Reach Landmark Consensus on Delivering Intensive Leukemia Drug CPX-351 Outside the Hospital. Scienmag. https://scienmag.com/experts-reach-landmark-consensus-on-delivering-intensive-leukemia-drug-cpx-351-outside-the-hospital/
Nathaniel Bowman. “Experts Reach Landmark Consensus on Delivering Intensive Leukemia Drug CPX-351 Outside the Hospital.” Scienmag, 12 September 2026, https://scienmag.com/experts-reach-landmark-consensus-on-delivering-intensive-leukemia-drug-cpx-351-outside-the-hospital/. Accessed 12 September 2026.
Nathaniel Bowman. “Experts Reach Landmark Consensus on Delivering Intensive Leukemia Drug CPX-351 Outside the Hospital.” Scienmag. September 12, 2026. https://scienmag.com/experts-reach-landmark-consensus-on-delivering-intensive-leukemia-drug-cpx-351-outside-the-hospital/
Copy citation Download RIS
Tags: acute myeloid leukaemiaambulatory careAML-MRCchemotherapyCPX-351Delphi consensushaematologyhealthcare system capacity and leukemia treatmentintensive chemotherapy for AMLinternational consensus on leukemia careLeukemia drug CPX-351 outpatient administrationliposomal cytarabine daunorubicin deliveryliposomal cytarabine-daunorubicinmanaging therapy-related AML outside hospitalmodified Delphi methodology in oncologyoutpatient careoutpatient leukemia treatment guidelinespatient selectionpharmacokinetics of CPX-351Quality of Lifesafety protocols for outpatient chemotherapyshifting leukemia treatment from inpatient to outpatientt-AMLtailored treatment for AML with myelodysplasia-related changes
